UPJOHN's ROGAINE Rx-TO-OTC SWITCH APPLICATION WILL BE REVIEWED
This article was originally published in The Tan Sheet
Executive Summary
UPJOHN's ROGAINE Rx-TO-OTC SWITCH APPLICATION WILL BE REVIEWED by FDA's Nonprescription Drugs Advisory Committee at a July 27 meeting, FDA announced in a June 24 Federal Register notice. Upjohn submitted an NDA for the Rx-to-OTC switch of Rogaine (minoxidil 2% topical solution) as a hair growth stimulant for male pattern baldness (androgenetic alopecia). The meeting will begin at 2 p.m. on July 27 in Conference Rooms D & E of FDA's Parklawn Building, 5600 Fishers Lane, Rockville, Md.